RecruitingPhase 3LSD
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
Sponsored by Definium Therapeutics US, Inc.
NCT ID
NCT06741228
Target Enrollment
200 participants
Start Date
2024-12-11
Est. Completion
2026-11
About This Study
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Conditions Studied
Interventions
- •Placebo
- •MM120 (LSD D-Tartrate)
Eligibility
Age:18 Years - 74 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: 1. Diagnosis of GAD per DSM-5 2. Male or female aged 18 to 74 3. HAM-A Total Score ≥20 Exclusion Criteria: 1. Certain psychiatric disorders (other than generalized anxiety disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine) 4. Any clinically significant unstable illness
Study Locations (36)
Lighthouse Psychiatry
Gilbert, Arizona, United States
Scottsdale Research Institute
Scottsdale, Arizona, United States
Kadima Neuropsychiatry Institute
La Jolla, California, United States
UCSF Department of Neurology
San Francisco, California, United States
Psychedelic Science Institute
Santa Monica, California, United States
Mountain View
Denver, Colorado, United States
Clinical Neuroscience Solutions Inc.
Jacksonville, Florida, United States
Accel Research Sites - Lakeland CRU
Lakeland, Florida, United States
Segal Trials
Lauderhill, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
+26 more locations